Bristol-Myers Squibb Company (ETR: BRM)
Germany
· Delayed Price · Currency is EUR | Market Cap | 112.18B |
| Revenue (ttm) | 42.53B |
| Net Income (ttm) | -6.51B |
| Shares Out | n/a |
| EPS (ttm) | -3.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 2.20 (4.03%) |
| Ex-Dividend Date | Jan 3, 2025 |
| Volume | 371 |
| Open | 55.92 |
| Previous Close | 54.75 |
| Day's Range | 55.28 - 55.92 |
| 52-Week Range | 36.42 - 58.32 |
| Beta | 0.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 6, 2025 |
About ETR: BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esop... [Read more]
Financial Performance
In 2023, BRM's revenue was $45.01 billion, a decrease of -2.50% compared to the previous year's $46.16 billion. Earnings were $8.03 billion, an increase of 26.84%.
Financial numbers in USD Financial StatementsNews
Bristol Myers Squibb's (BMY) Opdivo Qvantig Approved for NSCLC Treatment
Bristol Myers Squibb's (BMY) Opdivo Qvantig Approved for NSCLC Treatment
U.S. Food and Drug Administration Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo (nivolumab) Indications1,2
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use,...
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
Opdivo Qvantig is the first and only subcutaneously administered PD-1 inhibitor 1 Given over three- to five-minutes, Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety prof...
FDA Approval of Injectable Opdivo: Bristol Myers Squibb Fights Off Patent Cliff Concerns
FDA Approval of Injectable Opdivo: Bristol Myers Squibb Fights Off Patent Cliff Concerns
Bristol-Myers gets EU okay for Opdivo/Yervoy combo
Bristol-Myers Squibb (BMY) said it has received E.U. approval for Opdivo in combination with Yervoy as a first-line treatment for certain types of colorectal cancer.
Bristol-Myers Squibb meets main goal in late-stage trials of its psoriatic arthritis treatment
Bristol-Myers Squibb Co (BMY) Announces Positive Phase 3 Trial Results for Sotyktu in Psoriatic ...
Bristol-Myers Squibb Co (BMY) Announces Positive Phase 3 Trial Results for Sotyktu in Psoriatic Arthritis
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
Bristol Myers Squibb (NYSE: BMY) today announced results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), the pivotal Phase 3 trials evaluating the efficacy and safety of Sotyktu (deucravac...
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025. Despite strong fundame...
Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 Prospects
Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
Bristol Myers Squibb Stock Earns 83 RS Rating
Bristol Myers Squibb sees its Relative Strength Rating reach the 80-plus level.
Empowering Early Lung Cancer Detection: Bristol-Myers Squibb Co (BMY) Initiatives
Empowering Early Lung Cancer Detection: Bristol-Myers Squibb Co (BMY) Initiatives
Bristol-Myers: Still An Opportunity Yielding Over 4%
Bristol-Myers' strategic acquisitions are expected to boost future EPS and financial stability. See why I rate BMY stock a strong buy.
Bristol-Myers Squibb Shares Rise After Analyst Upgrades, Positive Pipeline Outlook
Bristol-Myers Squibb Inc. (NYSE: BMY) shares saw are trading higher Monday. Jefferies ... Full story available on Benzinga.com
Bristol-Myers upgraded to buy by Jefferies
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Stifel ra...
Bristol-Myers Squibb Company files for automatic mixed securities shelf
Bristol-Myers Squibb Co (BMY) Announces Increased Quarterly Dividend
Bristol-Myers Squibb Co (BMY) Announces Increased Quarterly Dividend
Bristol-Myers Squibb Company raises quarterly dividend by 3.3% to $0.62/share
Bristol Myers Squibb Announces Dividend Increase
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. ...
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
Bristol Myers Squibb (NYSE: BMY) announced results from 18 presentations reinforcing its leadership in cell therapy, with data demonstrating efficacy, durability and safety of currently available ther...
Bristol-Myers Squibb Company (BMY) Citi's 2024 Global Healthcare Conference (Transcript)
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Why Is Purple Biotech Stock Trading Higher On Monday?
On Monday, Purple Biotech Ltd (NASDAQ: PPBT) reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in pati...